Idorsia Ltd (IDIA.S)
ZURICH, April 18 Swiss biotech Idorsia said on Thursday that all four clinical trials of its late-stage drug hopefuls were "on track" as it confirmed expectations of spending 570 million Swiss francs ($564 million) in the current year on the projects.
* IDORSIA ANNOUNCES FINANCIAL RESULTS FOR THE FIRST QUARTER 2019
* CFO says J&J was fully aware of Actelion DOJ probe (Adds details about possible deals, comments from CEO, CFO, details about Actelion settlement)
* ANNOUNCES FIRST PATIENT RECRUITED INTO REACT - PHASE 3 REGISTRATION STUDY WITH CLAZOSENTAN Source text for Eikon: Further company coverage: (Gdynia Newsroom)
BRIEF-Idorsia Starts Multiple-Dose Efficacy And Safety Study With Cenerimod For Treatment Of Systemic Lupus Erythematosus
* IDORSIA INITIATES A MULTIPLE-DOSE EFFICACY AND SAFETY STUDY WITH CENERIMOD FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS Source text for Eikon: Further company coverage: (Gdynia Newsroom)